Incretin physiology and pathophysiology from an Asian perspective

Journal of Diabetes Investigation

Volumn 6, Issue 5, 2015, Pages 495-507

  Cho, Young Min ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Asian; Incretin; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; SAXAGLIPTIN;

BODY MASS; BODY SIZE; BRAIN ISCHEMIA; CTRB1/2 GENE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EAST ASIAN; FOOD COMPOSITION; GENE; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC VARIABILITY; GIP GENE; GIPR GENE; GLP 1R GENE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; KCNQ1 GENE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TCF7L2 GENE; VOMITING; WFR1 GENE;

EID: 84940594276     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12305     Document Type: Review

References (91)

1. Nielsen C. Six major steps in animal evolution: are we derived sponge larvae? Evol Dev 2008; 10: 241-257.
2. Cho YM, Fujita Y, Kieffer TJ. Glucagon-like peptide-1: glucose homeostasis and beyond. Annu Rev Physiol 2014; 76: 535-559.
3. Cho YM, Kieffer TJ. K-cells and glucose-dependent insulinotropic polypeptide in health and disease. Vitam Horm 2010; 84: 111-150.
4. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 8-23.
5. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013; 4: 108-130.
6. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther 2012; 135: 247-278.
7. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
8. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
9. Huxley R, James WP, Barzi F, et al. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008; 9(Suppl 1): 53-61.
10. Ntuk UE, Gill JM, Mackay DF, et al. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490, 288 UK biobank participants. Diabetes Care 2014; 37: 2500-2507.
11. Kadowaki T, Sekikawa A, Murata K, et al. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes 2006; 30: 1163-1165.
12. Tanaka S, Horimai C, Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. Acta Diabetol 2003; 40(Suppl 1): S302-S304.
13. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl 1): S37-S43.
14. Matsumoto K, Miyake S, Yano M, et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
15. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.
16. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000; 49: 975-980.
17. Kim YI, Choi CS, Kim SW, et al. Changes in Serum true insulin and C-peptide levels during oral glucose tolerance test in Koreans with glucose intolerance. J Korean Diabetes Assoc 1998; 22: 192-198.
18. Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 2014; 37: 796-804.
19. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 2003; 4: 293-340.
20. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet 1962; 14: 353-362.
21. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-948.
22. Chang CL, Cai JJ, Lo C, et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Res 2011; 21: 21-32.
23. Saxena R, Hivert MF, Langenberg C, et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010; 42: 142-148.
24. Sathananthan A, Man CD, Micheletto F, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 2010; 33: 2074-2076.
25. Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet 2009; 18: 2388-2399.
26. Zimdahl H, Ittrich C, Graefe-Mody U, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 2014; 57: 1869-1875.
27. Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40: 1098-1102.
28. Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40: 1092-1097.
29. Mussig K, Staiger H, Machicao F, et al. Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 2009; 58: 1715-1720.
30. Schafer SA, Mussig K, Staiger H, et al. A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 2009; 52: 1075-1082.
31. 't Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013; 62: 3275-3281.
32. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
33. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 2013; 56: 965-972.
34. Vollmer K, Gardiwal H, Menge BA, et al. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab 2009; 94: 1379-1385.
35. Calanna S, Christensen M, Holst JJ, et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 2013; 36: 3346-3352.
36. Han SJ, Kim HJ, Choi SE, et al. Incretin secretion and serum DPP-IV activity in Korean patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: e49-e52.
37. Lee S, Yabe D, Nohtomi K, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010; 57: 119-126.
38. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japansese: comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest 2010; 1: 56-59.
39. Oh TJ, Kim MY, Shin JY, et al. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol 2014; 80: 221-227.
40. Kamoi K, Shinozaki Y, Furukawa K, et al. Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus. Endocr J 2012; 59: 353-363.
41. Yabe D, Watanabe K, Sugawara K, et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J Diabetes Invest 2012; 3: 70-79.
42. Lee SA, Kim YR, Yang EJ, et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2013; 98: 2553-2561.
43. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
44. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
45. Bagger JI, Knop FK, Lund A, et al. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 737-745.
46. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
47. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713.
48. Holst JJ, Knop FK, Vilsboll T, et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34(Suppl 2): S251-S257.
49. Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
50. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010; 59: 1117-1125.
51. Ostoft SH, Bagger JI, Hansen T, et al. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young-type 2 and type 3. Diabetes 2014; 63: 2838-2844.
52. Kosinski M, Knop FK, Vedtofte L, et al. Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. Regul Pept 2013; 186: 104-107.
53. Hojberg PV, Vilsboll T, Rabol R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52: 199-207.
54. Laferrere B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007; 30: 1709-1716.
55. Vethakkan SR, Walters JM, Gooley JL, et al. The incretin response after successful islet transplantation. Transplantation 2014; 97: e9-e11.
56. Hamasaki AHN, Muraoka A, Yamane S, et al. Not glucose tolerance but obesity impairs the numerical incretin effect in Japanese subjects. Diabetologia 2011; 54: S217.
57. Oh TJ, Park KS, Cho YM. Correlation of the incretin effect with first and second phase insulin secretion in Koreans with various glucose tolerance statuses. Clin Endocrinol 2014; doi:10.1111/cen.12623.
58. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
59. Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care 2013; 36: 1789-1796.
60. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.
61. Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012; 46: 1453-1469.
62. Kim YG, Hahn S, Oh TJ, et al. Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 900-909.
63. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
64. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
65. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
66. Aso Y, Ozeki N, Terasawa T, et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Transl Res 2012; 159: 25-31.
67. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27-e28.
68. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
69. Jensen CC, Cnop M, Hull RL, et al. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 2002; 51: 2170-2178.
70. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab 2013; 28: 262-274.
71. Chitnis AS, Ganz ML, Benjamin N, et al. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther 2014; 31: 986-999.
72. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361-372.
73. Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009; 49: 39-49.
74. BYETTA Label Info. U.S. Food and Durg Administration, 2005. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021773s029s030lbl.pdf
75. Victoza Label Info. U.S. Food and Durg Administration, 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf
76. Iwasaki M, Hoshian F, Tsuji T, et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Invest 2012; 3: 464-467.
77. Senmaru T, Fukui M, Kobayashi K, et al. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Invest 2012; 3: 498-502.
78. Jakubowicz D, Froy O, Ahren B, et al. Incretin, insulinotropic and glucose-lowering effects of whey protein pre-load in type 2 diabetes: a randomised clinical trial. Diabetologia 2014; 57: 1807-1811.
79. Yabe D, Kuwata H, Iwasaki M, et al. Effects of fish or meat intake before and after rice on postprandial glucose excursions and incretin secretion in type 2 diabetes: meal sequence as a novel target in dietary therapies for diabetes. Diabetes 2014; 63: LB12.
80. Yabe D, Seino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe? J Diabetes Invest 2014; 5: 475-477.
81. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
82. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381: 117-124.
83. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370: 794-797.
84. Yabe D, Kuwata H, Kaneko M, et al. Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. Diabetes Obes Metab 2014;. doi:10.1111/dom.12381.
85. Chou HC, Chen WW, Hsiao FY. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study. Drug Saf 2014; 37: 521-528.
86. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
87. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
88. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215.
89. Hu C, Zhang R, Wang C, et al. Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One 2010; 5: e15542.
90. Franks PW, Rolandsson O, Debenham SL, et al. Replication of the association between variants in WFS1 and risk of type 2 diabetes in European populations. Diabetologia 2008; 51: 458-463.
91. Han X, Luo Y, Ren Q, et al. Implication of genetic variants near SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, FTO, TCF2, KCNQ1, and WFS1 in type 2 diabetes in a Chinese population. BMC Med Genet 2010; 11: 81.